β-Hydroxybutyrate Alleviates Low Glucose-Induced Apoptosis via Modulation of ROS-Mediated p38 MAPK Signaling
Cixia Li1, Xuejun Chai2, Jiarong Pan1
1College of Veterinary Medicine, Northwest A&F University, Yangling, Shaanxi, 712100, People's Republic of China.
Abstract:
Hypoglycemia has emerged as a prominent complication in anti-diabetic drug therapy or negative energy balance of animals, which causes brain damage, cognitive impairment, and even death. Brain injury induced by hypoglycemia is closely related to oxidative stress and the production of reactive oxygen species (ROS). The intracellular accumulation of ROS leads to neuronal damage, even death. Ketone body β-hydroxybutyrate (BHBA) not only serves as alternative energy source for glucose in extrahepatic tissues, but is also involved in cellular signaling transduction. Previous studies showed that BHBA reduces apoptosis by inhibiting the excessive production of ROS and activation of caspase-3. However, the effects of BHBA on apoptosis induced by glucose deprivation and its related molecular mechanisms have been seldom reported. In the present study, PC12 cells and primary cortical neurons were used to establish a low glucose injury model. The effects of BHBA on the survival and apoptosis in a glucose deficient condition and related molecular mechanisms were investigated by using flow cytometry, immunofluorescence, and western blotting. PC12 cells were incubated with 1 mM glucose for 24 h as a low glucose cell model, in which ROS accumulation and cell mortality were significantly increased. After 24 h and 48 h treatment with different concentrations of BHBA (0 mM, 0.05 mM, 0.5 mM, 1 mM, 2 mM), ROS production was significantly inhibited. Moreover, cell apoptosis rate was decreased and survival rate was significantly increased in 1 mM and 2 mM BHBA groups. In primary cortical neurons, at 24 h after treatment with 2 mM BHBA, the injured length and branch of neurites were significantly improved. Meanwhile, the intracellular ROS level, the proportion of c-Fos+ cells, apoptosis rate, and nuclear translocation of NF-κB protein after treatment with BHBA were significantly decreased when compared with that in low glucose cells. Importantly, the expression of p38, p-p38, NF-κB, and caspase-3 were significantly decreased, while the expression of p-ERK was significantly increased in both PC12 cells and primary cortical neurons. Our results demonstrate that BHBA decreased the accumulation of intracellular ROS, and further inhibited cell apoptosis by mediating the p38 MAPK signaling pathway and caspase-3 apoptosis cascade during glucose deprivation. In addition, BHBA inhibited apoptosis by activating ERK phosphorylation and alleviated the damage of low glucose to PC12 cells and primary cortical neurons. These results provide new insight into the anti-apoptotic effect of BHBA in a glucose deficient condition and the related signaling cascade.
Insights
Beta-hydroxybutyrate (BHBA) protects against glucose deprivation-induced neuronal damage by reducing oxidative stress and apoptosis. BHBA activates ERK phosphorylation and inhibits p38 MAPK signaling, offering neuroprotection in low glucose conditions.
Area of Science:
- Neuroscience
- Cell Biology
- Biochemistry
Background:
- Hypoglycemia, a complication of diabetes treatment or negative energy balance, causes neuronal damage, cognitive impairment, and death due to oxidative stress and reactive oxygen species (ROS).
- Beta-hydroxybutyrate (BHBA), a ketone body, serves as an alternative energy source and has shown potential in reducing apoptosis by inhibiting ROS and caspase-3 activation.
Purpose of the Study:
- To investigate the effects of BHBA on apoptosis induced by glucose deprivation in neuronal cells.
- To elucidate the molecular mechanisms underlying BHBA's neuroprotective effects in a glucose-deficient environment.
Main Methods:
- Establishment of a low glucose injury model using PC12 cells and primary cortical neurons.
- Treatment with varying concentrations of BHBA.
- Assessment of cell survival, apoptosis rates, ROS production, neurite injury, and key protein expressions (p38, p-p38, NF-κB, caspase-3, p-ERK) using flow cytometry, immunofluorescence, and western blotting.
Main Results:
- BHBA significantly inhibited ROS production and decreased apoptosis rates in PC12 cells and primary cortical neurons under low glucose conditions.
- BHBA treatment increased cell survival rates and improved neurite integrity in primary cortical neurons.
- BHBA modulated intracellular signaling pathways, decreasing p38 MAPK, NF-κB, and caspase-3 activity while increasing ERK phosphorylation.
Conclusions:
- BHBA exerts neuroprotective effects against glucose deprivation by reducing oxidative stress and inhibiting apoptosis.
- BHBA's mechanism involves mediating the p38 MAPK signaling pathway and caspase-3 cascade, alongside activating ERK phosphorylation.
- These findings highlight BHBA's potential therapeutic role in managing hypoglycemia-induced brain injury.
Related Concept Videos
Hypoglycemia and Glucagon
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Cell Specific Gene Expression
Oral Hypoglycemic Agents: Biguanides and Glitazones
PI3K/mTOR/AKT Signaling Pathway
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...


